Insights from Research on Corporate Venture in Medtech

Medcity New’s article discussing the findings from our research on which medtech corporate venture arms are the best partners:

The shift in the stage of investment and where the perceived opportunities in biotech are have had a significant impact. Pharma corporate venture investors have broadened their interest from late stage to earlier stages of investment. Priorities have also shifted from the next blockbuster drug to more personalized treatments.

One of the consistent criticisms of corporate investors is the imperfect balance between strengthening the core business and the investment target.

Read the article in its entirety here.

Lee Drucker

Share
Published by
Lee Drucker

Recent Posts

Another Court Holds That Sharing Legal Memorandum With Potential Litigation Funders Does Not Make Them Discoverable

There is a growing body of case law across multiple jurisdictions (including those that regularly…

10 months ago

A New York Appellate Court Weighs in on Litigation Funding Disclosure: Relevance is Paramount

As litigation funding becomes more normalized, the disclosure of litigation funding arrangements is a much…

11 months ago

The Argument for Why Counsel Have an Ethical Duty to Inform Clients About Litigation Finance

Recently, I met a General Counsel of a mid-cap company who had only just learned…

1 year ago

Litigation Funding Disclosure in Delaware: Emerging Standard?

Mandatory disclosure of litigation funding has arrived in the District of Delaware — at least…

1 year ago

What a Litigation Funder Learned from A Litigation Funding Conference

I recently attended the LITFINCON conference in Houston, Texas.   This was my first in-person…

2 years ago